Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC–MS/MS
Biomedical Chromatography · 2026
DOI: 10.1002/bmc.70599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Joshua J Deppas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Deoxyribonucleosides, Ribonucleosides, DNA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Deoxyuridine (dUrd) is often misincorporated into genomic DNA in cancer patients receiving antimetabolite chemotherapy. This activates base excision repair and recruits ataxia telangiectasia‐mutated and Rad3‐related (ATR), which coordinates DNA repair with nucleotide metabolism by facilitating ribonucleotide reductase (RNR) activity. Ceralasertib (AZD6738) is the most clinically advanced ATR inhibitor (ATRi) and may abrogate this regulatory pathway and diminish RNR‐mediated deoxynucleotide triphosphate synthesis. To further understand ATRi‐induced dUrd misincorporation, we developed a highly sensitive LC–MS/MS method to quantitate: deoxyuridine, uridine, guanosine, adenosine, cytidine, thymidine, deoxyguanosine, deoxyadenosine, and deoxycytidine from digested genomic DNA. Assay application was demonstrated with genomic DNA digested from multiple murine cell lines treated with ceralasertib. Chromatographic separation was achieved with an Inertsil ODS‐3 (150 × 2.1 mm, 3 μm) column and a gradient elution program of 0.1% formic acid in water and 0.1% formic acid in methanol over an 18‐min run time. Detection was performed on a SCIEX 6500+ tandem mass spectrometer. The method proved to be accurate (90.8%–114.2%) and precise (< 7.73% CV) across analytes. Freeze–thaw stability (106.4%–114.3%), stability for 12 months at −80°C (88.7%–113.7%), and stability for 4 h at room temperature (104.1%–114.0%) were acceptable across QCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
ORCID-Profile: Joshua J Deppas, Reyna Jones, Robert A Parise, Pinakin Pandya, Christopher J Bakkenist, Jan H Beumer
Förderung
- NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- UPMC Hillman Cancer Center
- Community Foundation of Warren County
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Deppas, J. J., Jones, R., Parise, R. A., Pandya, P., Bakkenist, C. J., & Beumer, J. H. (2026). Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC–MS/MS. Biomedical Chromatography. https://doi.org/10.1002/bmc.70599
Vancouver
Deppas JJ, Jones R, Parise RA, Pandya P, Bakkenist CJ, Beumer JH. Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC–MS/MS. Biomedical Chromatography. 2026. doi:10.1002/bmc.70599
BibTeX
@article{Deppas2026,
author = {Deppas, Joshua J and Jones, Reyna and Parise, Robert A and Pandya, Pinakin and Bakkenist, Christopher J and Beumer, Jan H},
title = {Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC–MS/MS},
journal = {Biomedical Chromatography},
year = {2026},
doi = {10.1002/bmc.70599}
}
EUVIMED